Full Picture

Article analysis:

The article is generally reliable and trustworthy as it provides evidence from a study conducted on 303 patients using the FDA approved cobas® 4800 HPV and REBA HPV-ID® assays to detect high risk human papillomaviruses (HR-HPVs). The results showed that the HR-HPV detection rates of these assays were comparable, with cobas® 4800 detecting 72.28% (219) and REBA HPV-ID® detecting 71.62% (217) of HR-HPVs positive cases, with HPV16 detection rates of 35.64% (108) and 30.69% (93), respectively. The article also provides evidence from other studies to support its claims, such as Bray et al.'s Global Cancer Statistics 2018 study which found that persistent infection with high risk human papillomaviruses has long been known to induce cervical cancer progression, as well as Walboomers et al.'s Human Papillomavirus is a Necessary Cause of Invasive Cervical Cancer Worldwide study which found that human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

The article does not appear to be biased or one sided in its reporting as it presents both sides equally by providing evidence from multiple studies to support its claims, including those mentioned above as well as Schiffman et al.'s Human Papillomavirus Testing in the Prevention of Cervical Cancer study which found that human papillomavirus testing can help prevent cervical cancer in women at risk for the disease. Furthermore, the article does not appear to contain any promotional content or partiality towards any particular product or company; rather it focuses on presenting evidence from multiple studies regarding the effectiveness of using FDA approved cobas® 4800 HPV and REBA HPV-ID® assays for detecting high risk human papillomaviruses in order to predict increased risk of cervical cancer progression in women at risk for the disease.

The article does note possible risks associated with using these tests such as false positives or false negatives which could lead to unnecessary treatments or missed diagnoses respectively; however it does not explore any counterarguments or missing points of consideration regarding this issue nor does it provide any further information about how these risks can be minimized or avoided altogether when using these tests for screening purposes. Additionally, while the article mentions that REBA HPV-ID® can be used to detect low risk types in high grade lesions that are HR-HPV negative, it does not provide any further information about how this test works nor what types of low risk HPVs it can detect specifically; thus leaving readers without a full understanding about this particular aspect mentioned in the article's conclusion section regarding potential uses for this test beyond just detecting high risk HPVs in order to predict increased risk for cervical cancer progression in women at risk for the disease